Your AI-Trained Oncology Knowledge Connection!
Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the considering factors for a patient with prostate cancer to undergo active surveillance versus active treatment.
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.
Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.
Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.
Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the development of the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) in the next 5 to 10 years.
Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses advancements in technology and safety of treatments for patients with head and neck cancer.
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses lessons learned from the recent IMmotion150 trial in renal cell carcinoma (RCC). The open-label, randomized study examined the PD-L1 inhibitor atezolizumab (Tecentriq) alone or in combination with bevacizumab (Avastin) versus sunitinib (Sutent) in patients with untreated advanced RCC.
John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of bone-targeting agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the advancements in the first- and second-line settings for treating patients with renal cell carcinoma (RCC). Jonasch shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.
E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses challenges facing PSA testing for patients with prostate cancer.
Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses high-penetrance genetic syndromes in patients with prostate cancer.
Maki Tanioka, MD, PhD, UNC Lineberger Comprehensive Cancer Center, discusses the results of the phase III CALGB 40601 (Alliance) study in HER2-positive breast cancer.
Thomas Powles, MD, Barts Cancer Institute, discusses the future of durvalumab in the treatment of bladder cancer.
Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.
Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.
Stacie Levine, MD, associate professor of Medicine, director, Geriatrics and Hospice and Palliative Medicine Fellowship Program, University of Chicago Medicine, discusses the benefits of palliative care for patients with non–small cell lung cancer (NSCLC).
Noah S. Kornblum, MD, assistant professor of medicine, Albert Einstein College of Medicine, attending physician of medicine, Montefiore-Einstein Center for Cancer Care, discusses the results from the PrECOG 0102 study, which explored the addition of everolimus (Afinitor) to fulvestrant (Faslodex) as a treatment for patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer.
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses recent therapeutic advancements in the field of mantle cell lymphoma (MCL).
Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses the type of milestone that immunotherapy has had on the field of lung cancer.
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the side effects associated with immunotherapy in genitourinary cancers.
Joshua Sabari, MD, medical oncology fellow, Memorial Sloan Kettering Cancer Center, discusses the future that immunotherapy has in the field of small cell lung cancer (SCLC).
Nancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses current immunotherapy research being conducted in the field of osteosarcoma.
Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses NTRK rearrangement in patients with lung cancer.
Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.
Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses what he would like to see accomplished in the field of ovarian cancer over the next year.
Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer at Winship Cancer Institute of Emory University, discusses recent advancements in the field of multiple myeloma.
Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses PI3 kinase inhibitors in patients with chronic lymphocytic leukemia (CLL).
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses next steps for taxanes following the TAXYNERGY trial in prostate cancer.
Fred Saad, MD, professor and chief of Urology, director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses results of a trial that investigated early use of radium-223 dichloride (Xofigo) in patients with asymptomatic metastatic castration-resistant prostate cancer.
Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).
